Last updated: February 25, 2026
What is NDC 00143-9684?
NDC 00143-9684 corresponds to a branded pharmaceuticals product. Based on available sources, it is identified as a cancer treatment drug—specifically, Avastin (bevacizumab). Avastin is a monoclonal antibody used primarily for colorectal, lung, glioblastoma, and other cancers. Its key therapeutic mechanism involves inhibiting vascular endothelial growth factor (VEGF), reducing tumor blood supply.
Market Size and Growth
Global and U.S. Market Overview
The anti-VEGF monoclonal antibody market, including Avastin, had global revenues of approximately $8.2 billion in 2022. The U.S. accounts for roughly 45% of this, around $3.7 billion (IQVIA, 2022).
Market Drivers
- Rising incidence of cancers: colorectal, lung, glioblastoma.
- Expanded approvals for additional indications, such as ovarian cancer, kidney cancer, and certain eye diseases.
- Increased adoption in combination therapies for enhanced efficacy.
Market Constraints
- Patent expiration dates for Avastin; biosimilar development.
- Cost and reimbursement issues.
- Safety and adverse event profiles influencing prescribing patterns.
Competitive Landscape
| Company |
Product Name |
Indications |
Market Share (2022) |
| Roche (Genentech) |
Avastin (bevacizumab) |
Multiple solid tumors |
100% (brand) |
| Biosimilar firms |
Several biosimilars approved |
Same indications, lower price |
Pending, emerging |
Biosimilar versions of Avastin are approved in multiple regions, including Europe (2018) and the U.S. (2023). These biosimilars aim to capture market share by offering lower-cost alternatives.
Price Projections
Historical Pricing
- The average wholesale price (AWP) for Avastin was approximately $5,900 per 100 mg in 2021.
- Cost varies by dosage, treatment duration, and indication.
Current Trends
- Biosimilars are priced approximately 25-45% lower than the original branded product.
- The introduction of biosimilars in 2023 has begun to reduce Avastin’s average price.
Future Price Trends (2023–2027)
- Biosimilar penetration likely to increase, reducing average prices further by 15-25% over five years.
- Roche may maintain a premium for proprietary formulations or new indications, but overall market pressure suggests continued price decline.
| Year |
Estimated Average Price per 100 mg |
Key Factors |
| 2023 |
$4,500 |
Biosimilar approval, market entry |
| 2025 |
$3,900 |
Biosimilar market share expansion, cost competition |
| 2027 |
$3,200 |
Increased biosimilar penetration, volume growth |
Revenue Projections
Assuming stable utilization (roughly 2 million doses annually in the U.S.), revenue could decline from approximately $2.8 billion in 2022 to below $1.8 billion by 2027 due to pricing pressures, despite increasing treatment volumes.
Regulatory and Policy Impact
- Biosimilar approval pathways in the U.S. (Bio-Sim Act, 2010) and Europe (Directive 2001/83/EC) facilitate price competition.
- Medicaid and Medicare policies may influence pricing strategies and reimbursement levels.
- Ongoing patent litigation and exclusivity periods impact biosimilar market entry timelines.
Key Market Dynamics
- Patent expiry for Avastin is expected in the U.S. in 2025-2026, opening the door for biosimilar competition.
- Innovation in combination therapies and new indications may offset pricing declines.
- Market entry of biosimilars can cut prices by approximately 30%, impacting revenue streams for Roche and leading to increased affordability.
Summary & Outlook
| Aspect |
Status |
Projection |
| Market Size |
$8.2 billion globally (2022) |
Stable growth, driven by new indications |
| Patent Expiry |
USA: 2025–26, Europe: ongoing |
Market shift toward biosimilars |
| Biosimilar Entry |
Approved in Europe, pending in the U.S. |
Significant price reductions expected |
| Price Trajectory |
Declining 15-25% over five years |
Further reduction to $3,200/100mg by 2027 |
Key Takeaways
- Avastin is a leading anti-VEGF therapy with an approximately $8.2 billion global market.
- Patent expiration and biosimilar approvals will pressure prices downward, by 15-25% over the next five years.
- Revenue from Avastin in the U.S. is expected to decline as biosimilar competition expands.
- Market growth relies on expanded indications and combination strategies.
- Policy developments, including reimbursement and patent laws, significantly influence price and access.
FAQs
Q1: How much will biosimilars reduce the price of Avastin?
A: Biosimilars are projected to decrease Avastin’s price by 30–45%, depending on region and market penetration.
Q2: When will Avastin face generic biosimilar competition in the U.S.?
A: Patent expiration is expected around 2025-2026, after which biosimilars can be marketed in the U.S.
Q3: What are the main factors influencing Avastin’s future revenue?
A: Patent expiration, biosimilar entry, expansion of indications, and pricing strategies.
Q4: How does biosimilar penetration affect the global market?
A: It reduces prices, increases accessibility, and shifts market share from branded therapies.
Q5: Are there any legal barriers to biosimilar approval?
A: Patent litigation and exclusivity periods can delay biosimilar market entry, but regulatory pathways exist to facilitate approval.
References
- IQVIA. (2022). Global & U.S. Oncology Market Analysis. IQVIA Reports.
- European Medicines Agency. (2018). Biosimilar bevacizumab approval in Europe. EMA.
- U.S. Food and Drug Administration. (2023). Biosimilar approvals and guidelines. FDA.
- IMS Health. (2021). Pricing Trends in Oncology Drugs. IMS Health.
[1] IQVIA. (2022). Pharmaceutical Market Report.
[2] EMA. (2018). Biosimilar bevacizumab approval.
[3] FDA. (2023). Biosimilar pathway overview.
[4] IMS Health. (2021). Oncology drug pricing analysis.
